Tumor Microenvironment-Responsive Lipid Nanoparticle for Blocking Mitosis and Reducing Drug Resistance in NSCLC

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Blocking mitosis is a key strategy for cancer cell death induction.
• Tumor cells utilize glycolysis, mediated by AMPK and PFKFB3, to sustain ATP supply and resist antimitotic drugs.
• Increased glutathione (GSH) in cancer cells, a result of glycolysis, presents a target for microenvironment-responsive drugs.

Purpose of the Study:

• To develop a novel drug delivery system for enhanced cancer therapy.
• To investigate the combined effect of blocking mitosis and inhibiting glycolysis in nonsmall cell lung cancer (NSCLC).
• To create a glutathione-triggered nanoparticle for targeted drug delivery and overcoming drug resistance.

Main Methods:

• Synthesis of a novel cationic lipid with disulfide bonds for nanoparticle formulation.
• Preparation of a glutathione-triggered lipid nanoparticle (2-DG@SLNP(siR)) encapsulating Plk1 siRNA and 2-deoxyglucose (2-DG).
• In vivo evaluation of the nanoparticle's efficacy in blocking mitosis and reducing drug resistance in NSCLC cells.

Main Results:

• The synthesized nanoparticle, 2-DG@SLNP(siR), successfully arrested the NSCLC cell cycle at the G2/M phase via Plk1 siRNA.
• 2-deoxyglucose effectively inhibited glycolysis in NSCLC cells.
• The nanoparticle demonstrated potential in reducing drug resistance in cancer cells.

Conclusions:

• The developed 2-DG@SLNP(siR) nanoparticle is an efficient platform for blocking mitosis and overcoming drug resistance in NSCLC.
• Targeting both mitosis and glycolysis simultaneously offers a promising strategy for cancer treatment.
• The GSH-triggered nature of the nanoparticle allows for microenvironment-responsive drug delivery.